全文获取类型
收费全文 | 55282篇 |
免费 | 3390篇 |
国内免费 | 1516篇 |
专业分类
耳鼻咽喉 | 390篇 |
儿科学 | 1018篇 |
妇产科学 | 667篇 |
基础医学 | 4533篇 |
口腔科学 | 1037篇 |
临床医学 | 5103篇 |
内科学 | 5694篇 |
皮肤病学 | 472篇 |
神经病学 | 3499篇 |
特种医学 | 1264篇 |
外国民族医学 | 6篇 |
外科学 | 5539篇 |
综合类 | 10415篇 |
现状与发展 | 1篇 |
一般理论 | 4篇 |
预防医学 | 5223篇 |
眼科学 | 934篇 |
药学 | 4616篇 |
126篇 | |
中国医学 | 7995篇 |
肿瘤学 | 1652篇 |
出版年
2024年 | 204篇 |
2023年 | 983篇 |
2022年 | 1766篇 |
2021年 | 2322篇 |
2020年 | 2130篇 |
2019年 | 2241篇 |
2018年 | 1922篇 |
2017年 | 1797篇 |
2016年 | 1685篇 |
2015年 | 1439篇 |
2014年 | 3491篇 |
2013年 | 3126篇 |
2012年 | 3086篇 |
2011年 | 3877篇 |
2010年 | 3535篇 |
2009年 | 2591篇 |
2008年 | 2396篇 |
2007年 | 2594篇 |
2006年 | 2415篇 |
2005年 | 1999篇 |
2004年 | 1614篇 |
2003年 | 1513篇 |
2002年 | 1037篇 |
2001年 | 922篇 |
2000年 | 763篇 |
1999年 | 695篇 |
1998年 | 537篇 |
1997年 | 515篇 |
1996年 | 413篇 |
1995年 | 460篇 |
1994年 | 428篇 |
1993年 | 328篇 |
1992年 | 329篇 |
1991年 | 290篇 |
1990年 | 249篇 |
1989年 | 243篇 |
1988年 | 247篇 |
1987年 | 204篇 |
1986年 | 197篇 |
1985年 | 417篇 |
1984年 | 409篇 |
1983年 | 325篇 |
1982年 | 357篇 |
1981年 | 353篇 |
1980年 | 342篇 |
1979年 | 304篇 |
1978年 | 270篇 |
1977年 | 244篇 |
1976年 | 182篇 |
1975年 | 108篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
32.
Katherine M. Duszynski Nicole L. Pratt John W. Lynch Jesia G. Berry Michael S. Gold 《Vaccine》2019,37(2):280-288
Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献33.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献34.
35.
36.
37.
目的探讨工作坊模式在护生压疮护理带教中的应用效果,为临床护理带教提供参考。方法选取2018年7月—2019年6月在医院实习的120名护生作为研究对象,随机分为对照组和观察组,各60名护生。对照组采用传统带教法进行压疮培训,观察组采用工作坊教学模式进行培训。培训结束后比较两组护生压疮知识的掌握程度即理论考核、技能操作成绩,教学效果满意度。结果观察组护生对压疮知识的掌握程度即理论考核成绩、技能操作考核成绩远远高于对照组,两组差异具有统计学意义(P<0.05)。95%的观察组护生对工作坊教学模式的效果表示满意,认为工作坊教学模式能够提高学习的兴趣、主动性和临床实践能力,对临床工作有很大帮助。结论工作坊教学模式应用于压疮护理的临床带教,能让护生亲身体验压疮护理的过程,并参与其中,将理论与实践相结合,更好地活跃课堂气氛,启发护生思考,提高护生对压疮理论和技能的掌握,为临床实际工作中压疮护理质量的提高奠定基础。 相似文献
38.
吴洁 《南京中医药大学学报》2019,35(4):376-378
回顾《内经》相关理论,指出痈脓病机关键在于气血凝滞、经络阻塞、脏腑失和,可分期论治。总结《金匮要略》治疗痈脓的方法,认为痈脓应尽早治疗,防邪深入;并根据证情辨证使用清热解毒,活血消散;排除脓毒,泄浊于外等治法。对现代临床仍具实用价值。 相似文献
39.
《Journal of pharmaceutical sciences》2019,108(10):3425-3433
This study aimed at evaluating how encapsulation in a regular nanocarrier (NC) (providing extended circulation time) or in a brain-targeting NC (providing prolonged circulation time and increased brain uptake) may influence the therapeutic index compared with the unformulated drug and to explore the key parameters affecting therapeutic performance using a model-based approach. Pharmacokinetic (PK) models were built with chosen PK parameters. For a scenario where central effect depends on area under the unbound brain concentration curve and peripheral toxicity relates to peak unbound plasma concentration, dose-effect and drug-side effect curves were constructed, and the therapeutic index was evaluated. Regular NC improved the therapeutic index compared with the unformulated drug due to reduced peripheral toxicity, while brain-targeting NC enhanced the therapeutic index by lowering peripheral toxicity and increasing central effect. Decreasing drug release rate or systemic clearance of NC with drug still encapsulated could increase the therapeutic index. Also, a drug with shorter half-life would therapeutically benefit more from a NC encapsulation. This work provides insights into how a NC for brain delivery should be optimized to maximize the therapeutic performance and is helpful to predict if and to what extent a drug with certain PK properties would obtain therapeutic benefit from nanoencapsulation. 相似文献
40.
正确编制“本年盈余与预算结余差异调节表”是公立医院执行《政府会计制度》的一大难点,现有的几种差异调节方法存在诸多不足,核算正确与否依赖会计人员的基本素质,而且工作量巨大。以财务会计与预算会计差异产生的基本原理为基础,利用计算机软件实时校验并自动登记差异,是简便、高效、准确编制“本年盈余与预算结余差异调节表”的方法,本文对此进行了举例说明。 相似文献